Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Treatment outcomes with ixekizumab in patients with moderate‐to‐severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies
Alice B. Gottlieb, J.‐P. Lacour, Neil J. Korman, et al.
Journal of the European Academy of Dermatology and Venereology (2016) Vol. 31, Iss. 4, pp. 679-685
Open Access | Times Cited: 52

Showing 1-25 of 52 citing articles:

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
Alan Menter, Bruce Strober, Daniel H. Kaplan, et al.
Journal of the American Academy of Dermatology (2019) Vol. 80, Iss. 4, pp. 1029-1072
Closed Access | Times Cited: 740
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
É. Sbidian, Anna Chaimani, I. García‐Doval, et al.
Cochrane library (2017)
Open Access | Times Cited: 301
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
É. Sbidian, Anna Chaimani, I. García‐Doval, et al.
Cochrane library (2020)
Open Access | Times Cited: 164
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
É. Sbidian, Anna Chaimani, I. García‐Doval, et al.
Cochrane library (2021) Vol. 2021, Iss. 12
Open Access | Times Cited: 135
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
É. Sbidian, Anna Chaimani, I. García‐Doval, et al.
Cochrane library (2022) Vol. 2022, Iss. 8
Open Access | Times Cited: 109
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
É. Sbidian, Anna Chaimani, Robin Guelimi, et al.
Cochrane library (2023) Vol. 2023, Iss. 7
Open Access | Times Cited: 92
Clinical Characteristics Associated With Response to Biologics in the Treatment of Psoriasis
Gustav Hjort, C. Schwarz, Lone Skov, et al.
JAMA Dermatology (2024) Vol. 160, Iss. 8, pp. 830-830
Closed Access | Times Cited: 9
Efficacy of risankizumab in patients with moderate‐to‐severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa‐1 and UltIMMa‐2 studies
Bruce Strober, Alan Menter, C. Leonardi, et al.
Journal of the European Academy of Dermatology and Venereology (2020) Vol. 34, Iss. 12, pp. 2830-2838
Open Access | Times Cited: 53
Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3
Kim Papp, Ken Gordon, Richard Langley, et al.
British Journal of Dermatology (2018)
Closed Access | Times Cited: 57
Diagnostic and therapeutic guidelines for plaque psoriasis - Brazilian Society of Dermatology
Marcelo Arnone, Maria Denise Fonseca Takahashí, André Vicente Esteves de Carvalho, et al.
Anais Brasileiros de Dermatologia (2019) Vol. 94, Iss. 2 suppl 1, pp. 76-107
Open Access | Times Cited: 50
Ixekizumab for the treatment of psoriasis: up-to-date
Sarah Craig, Richard B. Warren
Expert Opinion on Biological Therapy (2020) Vol. 20, Iss. 6, pp. 549-557
Closed Access | Times Cited: 50
Actualización práctica de las recomendaciones del Grupo de Psoriasis de la Academia Española de Dermatología y Venereología (GPS) para el tratamiento de la psoriasis con terapia biológica. Parte 1. «Conceptos y manejo general de la psoriasis con terapia biológica»
J.M. Carrascosa, L. Puig, I. Belinchón, et al.
Actas Dermo-Sifiliográficas (2021) Vol. 113, Iss. 3, pp. 261-277
Open Access | Times Cited: 39
Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA)
Thomas Graier, Wolfgang Weger, Constanze Jonak, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 21
Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis
Yahiya Y. Syed
American Journal of Clinical Dermatology (2017) Vol. 18, Iss. 1, pp. 147-158
Closed Access | Times Cited: 35
Efficacy of a second interleukin 17 inhibitor in patients with psoriasis: A systematic review and meta-analysis
Nikolai Loft, Anne‐Sofie Halling, Alexander Egeberg, et al.
Journal of the American Academy of Dermatology (2020) Vol. 84, Iss. 1, pp. 130-138
Closed Access | Times Cited: 29
Comparative Efficacy of Ustekinumab and Guselkumab in Improving Itch in Severe Psoriasis Patients
Ji Hoon Ryoo, Nam Gyoung Ha, Han Jin Jung, et al.
Annals of Dermatology (2025) Vol. 37
Open Access
Ixekizumab for the treatment of psoriasis: an update on new data since first approval
C. Blegvad, Lone Skov, Claus Zachariae
Expert Review of Clinical Immunology (2018) Vol. 15, Iss. 2, pp. 111-121
Closed Access | Times Cited: 32
Efficacy and safety of ixekizumab in patients with plaque psoriasis across different degrees of disease severity: results from UNCOVER-2 and UNCOVER-3
Lajos Kemény, Lovisa Berggren, M. Dossenbach, et al.
Journal of Dermatological Treatment (2018) Vol. 30, Iss. 1, pp. 19-26
Open Access | Times Cited: 29
PASI 100 response rates in moderate to severe psoriasis: a systematic literature review and analysis of clinical practice guidelines
I. Belinchón, E. Daudén, Carlos Ferrándiz Foraster, et al.
Journal of Dermatological Treatment (2021) Vol. 33, Iss. 3, pp. 1661-1669
Open Access | Times Cited: 22
Choosing the right biologic treatment for moderate-to-severe plaque psoriasis: the impact of comorbidities
Laura Mateu Arrom, L. Puig
Expert Review of Clinical Pharmacology (2024) Vol. 17, Iss. 4, pp. 363-379
Closed Access | Times Cited: 3
Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy
Alessandro Giunta, Alessandra Ventura, Maria Sole Chimenti, et al.
Drug Design Development and Therapy (2017) Vol. Volume 11, pp. 1643-1651
Open Access | Times Cited: 26
Efficacy of tildrakizumab for moderate‐to‐severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28
Kim Papp, Kristian Reich, Andrew Blauvelt, et al.
Journal of the European Academy of Dermatology and Venereology (2019) Vol. 33, Iss. 6, pp. 1098-1106
Open Access | Times Cited: 24
<p>An Update for the Clinician on Biologics for the Treatment of Psoriatic Arthritis</p>
Maria Sole Chimenti, A. D’antonio, Paola Conigliaro, et al.
Biologics (2020) Vol. Volume 14, pp. 53-75
Open Access | Times Cited: 23
Biologics Switch in Psoriasis
Ting‐Shun Wang, Tsen‐Fang Tsai
Immunotherapy (2019) Vol. 11, Iss. 6, pp. 531-541
Closed Access | Times Cited: 20
Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase 2b and 2 phase 3 trials in patients with moderate‐to‐severe chronic plaque psoriasis
Yves Poulin, M. Ramon, L. Rosoph, et al.
Journal of the European Academy of Dermatology and Venereology (2020) Vol. 34, Iss. 7, pp. 1500-1509
Closed Access | Times Cited: 19
Page 1 - Next Page

Scroll to top